Correlation of increased PARP14 and CCL26 expression in biopsies from children with eosinophilic esophagitis - 30/01/14
This work was supported by Public Health Service grants R01 AI095282, R01 HL093105, R01 DK076893, and U19 AI070235. |
|
Disclosure of potential conflict of interest: J. D. Sherrill has received research support from the Thrasher Research Fund. M. E. Rothenberg has received research support from the National Institutes of Health (NIH), the CURED Foundation, the Buckeye Foundation, and FARE; is a board member for the International Eosinophil Society Steering Committee and APFED Medical Panel; has received consulting fees from Immune Pharmaceuticals, Pluristem Pharmaceuticals, Receptos, Inc, and Novartis; has patents (planned, pending, or issued) with Cincinnati Children's Hospital Medical Center; receives royalties from Teva Pharmaceuticals for reslizumab; and has stock/stock options in Immune Pharmaceuticals. S. Gupta has received consulting fees from Meritage Pharma and NPS Pharmaceuticals, and has received lecture fees from Abbott Nutrition. M. H. Kaplan has received research support from the NIH. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 133 - N° 2
P. 577 - février 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?